Loading…
Xenetic Biosciences, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -85.7% over 5Y.
today you would have $116.59▼ -88.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.17 | $3.99 | $3.45 | $2.85 | $12.90 | $20.40 | $14.40 | $196.80 | $230.28 | $516.00 | |
| P/S | 2.5x | 1.7x | 2.5x | 2.1x | 2.5x | 14.9x | 40.8x | 530.3x | — | 2.2x | 12.4x |
| P/B |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| IMRNImmuron Ltd | $1.15 | — | 1.0x | — | -39.68% | $9.28M |
| APUSApimeds Pharmaceuticals US, Inc. | $6.30 | — | 9.7x | — | — | $9.51M |
| FBLGFibroBiologics, Inc. | $1.44 | — | 1.9x | — | -660.08% | $9.59M |
| TRAWTraws Pharma, Inc. | $0.59 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Company description provided by Yahoo Finance.
| 1.0x |
| 0.7x |
| 1.0x |
| 0.5x |
| 0.3x |
| 0.9x |
| 1.5x |
| 0.5x |
| 1.7x |
| 1.2x |
| 2.3x |
| EPS | -$1.58 | -$2.57 | -$2.71 | -$4.61 | -$5.50 | -$17.00 | -$63.30 | -$96.60 | -$49.20 | -$940.80 |
| Profit margin | -383.87% | -90.07% | -158.39% | -162.78% | -383.87% | -486.36% | -2493.11% | -74856.59% | — | -47.40% | -1806.87% |
| ROE | -56.97% | -36.25% | -65.93% | -42.21% | -48.01% | -30.69% | -89.18% | -74.22% | -73.65% | -25.14% | -335.24% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 5.3x |
| — |
| -433.36% |
| $9.07M |
| MBAIMBody AI Ltd. | $6.58 | 1.4x | 13.4x | — | — | $9.05M |
| IMNNImunon, Inc. | $1.60 | — | 3.9x | — | -429.72% | $8.98M |